secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065314
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA reports FY 2022 net loss of $17.1M; Vabysmo commercial payments begin
--------------------------------------------------------------------------

- FY 2022 revenue $6.0M vs $38.2M in 2021; net loss $17.1M vs net income $15.8M.
- Cash $57.8M at Dec 31, 2022; no debt.
- Received second Vabysmo commercial payment from Roche in Feb 2023; 0.5% interest in sales.
- Ebopiprant deal with Organon offers up to $378M milestones plus mid-single/low-teen royalties.
- Executive Chairman Owen Hughes and CIO Brad Sitko added to lead royalty acquisition strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/0001193125-23-065314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/d479992d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer